Two post-marketing requirement Phase III studies are ongoing in first- and second-line chemotherapy treatment of metastatic castration resistant prostate cancer patients. The clinical program is also evaluating Jevtana in pediatric patients with brain cancer (phase I/II ongoing). The main countries contributing to sales of Jevtana in 2015 were the U.S., France, Germany, Japan, Italy, Spain and the U.K. Taxotere Taxotere (docetaxel), a taxoid class derivative, inhibits cancer cell division by essentially ‘freezing’ the cell’s internal skeleton, which includes microtubules. Microtubules assemble and disassemble during a cell cycle. Taxotere promotes their assembly and blocks their disassembly, thereby preventing many cancer cells from dividing, which results in destroying many cancer cells. Taxotere is available in approximately 90 countries as an injectable solution. It has been approved for use in 11 indications in 5 different tumor types (breast, prostate, gastric, lung, and head and neck). The top four countries contributing to sales of Taxotere in 2015 were Japan, China, Taiwan and South Korea. Generics of docetaxel were launched in Europe, in the U.S., and in Japan. Eloxatin Eloxatin (oxaliplatin) is a platinum-based cytotoxic agent. Eloxatin, in combination with infusional administration of two other chemotherapy drugs, 5-fluorouracil/leucovorin (the FOLFOX regimen), is approved by the FDA for adjuvant treatment of people with stage III colon cancer who have had their primary tumors surgically removed. Eloxatin is in-licensed from Debiopharm and is marketed in approximately 70 countries worldwide. In 2013, Eloxatin received regulatory approval for advanced Hepatocellular Carcinoma (HCC) in China. Several generics of oxaliplatin are available globally, including Canada where Eloxatin lost exclusivity in December 2015. The main three countries contributing to sales of Eloxatin in 2015 were Canada, China and South Korea. Thymoglobulin Thymoglobulin (Anti-thymocyte Globulin) is a polyclonal anti-human thymocyte antibody preparation that acts as a broad immuno-suppressive and immuno-modulating agent. The product’s primary mechanism of action is T-cell depletion, which is complemented by a host of other immuno-modulating effects. Thymoglobulin is marketed in approximately 65 countries. Depending on the country, Thymoglobulin is indicated for the treatment and/or prevention of acute rejection in organ transplantation, immunosuppressive therapy in aplastic anemia, and/or the treatment and/or prevention of Graft-versus-Host Disease (GvHD) after allogeneic hematopoietic stem cell transplantation. The main countries contributing to Thymoglobulin sales in 2015 were the U.S., China, France, Japan and South Korea. Mozobil Mozobil (plerixafor injection) is a hematopoietic stem cell mobilizer indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). The main countries contributing to Mozobil sales in 2015 were the U.S., the U.K., Germany and France. Zaltrap Zaltrap (aflibercept) is a recombinant fusion protein, which acts as a soluble decoy receptor that binds to Vascular Endothelial Growth Factor-A (VEGF-A), Vascular Endothelial Growth Factor-B (VEGF-B) and placental growth factor (PIGF), preventing the bound VEGF from binding to their native receptors. VEGF-A is one of the mediators contributing to angiogenesis. VEGF-B and PlGF, related growth factors in the VEGF family, might contribute to tumor angiogenesis as well. In the U.S., Zaltrap is approved under the U.S. proper name ziv-aflibercept for use in combination with FOLFIRI, in patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. Zaltrap is marketed in the U.S. In the E.U., Zaltrap was approved in 2013 by the European Commission to treat mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. Zaltrap was approved in a fur
sanofi-adr (SNY:New York)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 42 96www.sanofi.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for SNY.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-ADR, please visit www.sanofi.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.